Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365378 | 0.94 | LRRK2 (0.40) | LRRK2MCHR1HDAC2CNR1HSD11B1 | |
| SCHEMBL17618585 | 0.94 | LRRK2 (0.40) | LRRK2MCHR1HDAC2CNR1HSD11B1 | |
| SCHEMBL17618516 | 0.94 | LRRK2 (0.40) | LRRK2MCHR1HDAC2CNR1HSD11B1 | |
| SCHEMBL17618482 | 0.92 | HDAC2 (0.39) | LRRK2MCHR1HDAC2CNR1HSD11B1 | |
| SCHEMBL19706194 | 0.89 | THRB (0.41) | LRRK2CNR1HSD11B1THRB | |
| SCHEMBL19706087 | 0.87 | HDAC2 (0.42) | LRRK2MCHR1HDAC2GPR6HSD11B1 | |
| SCHEMBL17618740 | 0.86 | ABL1 (0.38) | HSD11B1 | |
| SCHEMBL16776248 | 0.85 | GRM5 (0.38) | LRRK2CNR1 | |
| SCHEMBL16776287 | 0.84 | ABL1 (0.38) | — | |
| SCHEMBL17618702 | 0.83 | MEN1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | LRRK2 533/4885MCHR1 4256/4885HDAC2 50/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | LRRK2 533/4885MCHR1 4256/4885HDAC2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.